Use of background electrolytes to minimize flux variability during iontophoresis

• US 6,553,255 B1
• Filed: 10/27/2000
• Issued: 04/22/2003
• Est. Priority Date: 10/27/2000
• Status: Expired due to Fees

• Current Assignee: Aciont, Inc.
• Original Assignee: Aciont, Inc.
• Inventors: Higuchi, William I., Miller, David J., Li, Kevin
• Primary Examiner(s): Lazarus, Ira S.
• Assistant Examiner(s): NGUYEN, CAMTU TRAN
• Application Number:
  US09/698,697
• Time in Patent Office: 907 Days
• Field of Search: 604/20, 604/890.1, 604/21, 604/19, 604/501, 604/500
• US Class Current: 604/20
• CPC Class Codes: A61N 1/0416 Anode and cathode
• CPC Class Codes: A61N 1/0432 Anode and cathode
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428

Abstract

A device and method are provided that minimize the changes in flux encountered during iontophoresis and reduce inter-subject variability. For drug delivery, the active agent to be delivered is administered in conjunction with at least one background ion having a hindrance factor that changes at a faster rate than the hindrance factor of the active agent when an electrical current is applied. For analyte extraction, the extraction reservoir contains at least one background ion having a hindrance factor that changes at a faster rate than the hindrance factor of the background ions of the analyte in the tissue when an electrical current is applied.

Claims

1. An iontophoresis device that minimizes changes in active agent flux and reduces intertissue variability comprising:

a) a first electrode assembly adapted to be placed in agent transmitting relation with a body tissue comprising

(i) a pharmacologically active agent to be delivered; and

(ii) at least one background co-ion having a hindrance factor that changes at a faster rate than the hindrance factor of the active agent when an electrical current is applied;

b) a second electrode assembly adapted to be placed in ion transmitting relation with the body surface at a location spaced apart from the first electrode assembly; and

c) an electrical current source, electrically connected to the first and second electrode assemblies.

2. The device of claim 1, wherein the tissue is skin.

3. The device of claim 1, wherein the tissue is mucosal tissue.

4. The device of claim 1, wherein the background co-ion has an ionic charge that is identical to the ionic charge of the active agent.

5. The device of claim 1, wherein the background co-ion has an ionic charge that exceeds the ionic charge of the active agent.

6. The device of claim 1, wherein the background co-ion has an ionic charge of identical polarity to the active agent.

7. The device of claim 1, wherein the electrical current is direct current.

8. The device of claim 1, wherein the electrical current is alternating current.

9. The device of claim 1, wherein the electrical current comprises both alternating and directed current superimposed over each other.

10. The device of claim 1, wherein the background co-ion has an ionic size effective to minimize changes in active agent flux.

11. The device of claim 1, wherein the pharmacologically active agent is selected from the group consisting of:

analeptic agents;

analgesic agents;

anesthetic agents;

antiasthmatic agents;

antiarthritic agents;

anticancer agents;

anticholinergic agents;

anticonvulsant agents;

antidepressant agents;

antidiabetic agents;

antidiarrheal agents;

antiemetic agents;

antihelminthic agents;

antihistamines;

antihyperlipidemic agents;

antihypertensive agents;

anti-infective agents;

antiinflammatory agents;

antimigraine agents;

antineoplastic agents;

antiparkinsonisrn drugs;

antipruritic agents;

antipsychotic agents;

antipyretic agents;

antispasmodic agents;

antitubercular agents;

antiulcer agents;

antiviral agents;

anxiolytic agents;

appetite suppressants;

attention deficit disorder and attention deficit hyperactivity disorder drugs;

cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“

CNS”

) agents, beta-blockers and antiarrhythmic agents;

central nervous system stimulants;

diuretics;

genetic materials;

hormonolytics;

hypnotics;

hypoglycemic agents;

immunosuppressive agents;

rimuscle relaxants;

narcotic antagonists;

nicotine;

nutritional agents;

parasympatholytics;

peptide drugs;

psychostimulants;

sedatives;

steroids;

smoking cessation agents;

sympathomimetics;

tranquilizers; and

vasodilators.

12. The device of claim 1, wherein the pharmacologically active agent and the background co-ion are contained in a formulation additionally comprising a vehicle suitable for transdermal drug delivery.

13. The device of claim 1, wherein the first electrode assembly comprises a reservoir electrode adapted to be placed in agent transmitting relation with a body tissue and having a receptacle in which the pharmacologically active agent and the background co-ion are contained.

14. The device of claim 1, wherein said region of tissue has an area in the range of less than approximately 1 cm² to greater than 100 cm².

15. The device of claim 14, wherein the said region of tissue has an area in the range of 5 cm² to 30 cm².

16. The device. of claim 1, wherein the device is suitable for drug delivery that is carried out for a time period in the range of less than 10 minutes to greater than 24 hours.

17. The device of claim 16, wherein the device is suitable for drug delivery that is carried out for a time period in the range of about 1 hour to 12 hours.

18. The device of claim 16, wherein the device is suitable for drug delivery that is carried out for a time period in the range of about 12 hours to 24 hours.

19. In a method for delivering a pharmacologically active.agent across body. tissue using electrical current, the improvement comprising co-delivering with the active agent at least one background co-ion having a hindrance factor that changes at a faster rate than the hindrance factor of the active agent when an electrical current is applied, whereby changes in active agent flux are minimized and intertissue variability is reduced.

20. The method of claim 19, wherein the tissue is skin.

21. The method of claim 19, wherein the tissue is mucosal tissue.

22. A method for delivering a pharmacologically active agent across body tissue, comprising:

(a) placing in contact with the body tissue a composition comprising the pharmacologically active agent and at least one background co-ion having a hindrance factor that changes at a faster rate than the hindrance factor of the active agent when an electrical current is applied; and

(b) applying an electrical current to the region of tissue, the current of a voltage and duration effective to induce electroporation of the body surface in said tissue.

23. The method of claim 22, wherein the tissue is skin.

24. The method of claim 22, wherein the tissue is mucosal tissue.

25. The method of claim 22, wherein the background co-ion has an ionic charge that is identical to the ionic charge of the active agent.

26. The device of claim 22, wherein the background co-ion has an ionic charge that exceeds the ionic charge of the active agent.

27. The device of claim 22, wherein the background co-ion has an ionic charge of identical polarity to the active agent.

28. The method of claim 22, wherein the background co-ion has an ionic radius of at least about 5 angstroms.

29. The method of claim 22, wherein the electrical current is applied as a direct current.

30. The method of claim 22, wherein the electrical current is applied as an alternating current.

31. The method of claim 22, wherein the electrical current is applied as both alternating and direct current superimposed on one another.

32. The method of claim 22, wherein the background co-ion has an ionic size effective to minimize changes in active agent flux.

33. The method of claim 22, wherein the pharmacologically active agent is selected from the group consisting of:

analeptic agents;

analgesic agents;

anesthetic agents;

antiasthmatic agents;

antiarthritic agents;

anticancer agents;

anticholinergic agents;

anticonvulsant agents;

antidepressant agents;

antidiabetic agents;

antidiarrheal agents;

antiemetic agents;

antihelminthic agents;

antihistamines;

antihyperlipidemic agents;

antihypertensive agents;

anti-infective agents;

antiinflammatory agents;

antimigraine agents;

antineoplastic agents;

antiparkinsonism drugs;

antipruritic agents;

antipsychotic agents;

antipyretic agents;

antispasmodic agents;

antitubercular agents;

antiulcer agents;

antiviral agents;

anxiolytic agents;

appetite suppressants;

attention deficit disorder and attention deficit hyperactivity disorder drugs;

cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“

CNS”

) agents, beta-blockers and antiarrhythmic agents;

central nervous system stimulants;

diuretics;

genetic materials;

hormonolytics;

hypnotics;

hypoglycemic agents;

immunosuppressive agents;

muscle relaxants;

narcotic antagonists;

nicotine;

nutritional agents;

parasympatholytics;

peptide drugs;

psychostimulants;

sedatives;

steroids;

smoking cessation agents;

sympathomimetics;

tranquilizers; and

vasodilators.

34. The method of claim 22, wherein the pharmacologically active agent and the background co-ion are contained in a formulation additionally comprising a vehicle suitable for transdermal drug delivery.

35. The method of claim 22, wherein the pharmacologically active agent and the background co-ion are contained in a receptacle of a reservoir electrode in an iontophoretic drug delivery device, said reservoir electrode being placed in electrical contact with said region of the body surface during steps (a) and (b).

36. The device of claim 22, wherein said region of tissue has an area in the range of less than approximately 1 cm² to greater than 100 cm².

37. The device of claim 36, wherein the said region of tissue has an area in the range of 5 cm² to 30 cm².

38. The device of claim 22, wherein the device is suitable for drug delivery that is carried out for a time period in the range of less than 10 minutes to greater than 24 hours.

39. The device of claim 38, wherein the device is suitable for drug delivery that is carried out for a time period in the range of about 1 hour to 12 hours.

40. The device of claim 38, wherein the device is suitable for drug delivery that is carried out for a time period in the range of about 12 hours to 24 hours.

41. An iontophoresis device that minimizes changes in permeant flux and reduces intertissue variability comprising:

a) a first electrode assembly adapted to be placed in agent transmitting relation with a body tissue comprising

(i) a reservoir for containing a substance extracted from the body; and

(ii) at least one background ion having a hindrance factor that changes at a faster rate than the hindrance factor of the tissue background ions (the co-ion of the analyte) present in the body when an electrical current is applied;

b) a second electrode assembly adapted to be placed in ion transmitting relation with the body surface at a location spaced apart from the first electrode assembly; and

c) an electrical current source, electrically connected to the first and second electrode assemblies.

42. The device of claim 41, wherein the, tissue is skin.

43. The device of claim 41, wherein the tissue is mucosal tissue.

44. The device of claim 41, wherein the background ion has an ionic charge that is identical to the ionic charge of the co-ion transported with the permeant.

45. The device of claim 41, wherein the background ion has an ionic charge that exceeds the ionic charge of the co-ion transported with the permeant.

46. The device of claim 41, wherein the background ion has an ionic charge of opposite polarity to the co-ion transported with the permeant.

47. The device of claim 41, wherein the electrical current is direct current.

48. The device of claim 41, wherein the electrical current is alternating current.

49. The device of claim 41, wherein the electrical current comprises both alternating and directed current superimposed over each other.

50. The device of claim 41, wherein the background ion has an ionic size effective to minimize changes in permeant extraction through a body surface.

51. The device of claim 41, wherein the extracted substance is glucose.

52. The device of claim 41, wherein the extracted substance is phenylalanine.

53. The device of claim 41, wherein the extracted molecules are markers of disease states, pharmaceutical agents, administered to the subject, substances of abuse, ethanol, electrolytes, minerals, hormones, peptides, metal ions, nucleic acids, genes, enzymes or any metabolites, conjugates, or other derivations of the aforementioned products.

54. The device of claim 41, wherein the extracted permeant is an oligosaccharide, monosaccharide, organic acid, alcohol, fatty acid, cholesterol and cholesterol-based compound, amino acid, zinc, iron, copper, magnesium and potassium.

55. The device of claim 41, wherein the extracted permeant is a pharmacologically active agents that have been administered for either therapeutic or prophylactic treatment, including analeptic agents;

analgesic agents;

anesthetic agents;

antiasthmatic agents;

antiarthritic agents;

anticancer agents;

anticholinergic agents;

anticonvulsant agents;

antidepressant agents;

antidiabetic agents;

anrtidiarrheal agents;

antiemetic agents;

antihelminthic agents;

antihistamines;

antihyperlipidemic agents;

antihypertensive agents;

anti-infective agents;

antiinflammatory agents;

antimigraine agents;

antineoplastic agents;

antiparkinsonism drugs;

antipruritic agents;

antipsychotic agents;

antipyretic agents;

antispasmodic agents;

antitubercular agents;

antiulcer agents;

antiviral agents;

anxiolytic agents;

appetite suppressants;

attention deficit disorder and attention deficit hyperactivity disorder drugs;

cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“

CNS”

) agents, beta-blockers and antiarrhythmic agents;

central nervous system stimulants;

diuretics;

genetic materials;

hormonolytics;

hypnotics;

hypoglycemic agents;

immunosuppressive agents;

muscle relaxants;

narcotic antagonists;

nicotine;

nutritional agents;

parasympatholytics;

peptide drugs;

psychostimtilants;

sedatives;

steroids;

smoking cessation agents;

sympathomimetics;

tranquilizers;

vasodilators;

β

-agonist; and

tocolytic agents or metabolites thereof.

56. The device of claim 41, wherein the one or more substance is extracted concomitantly.

57. The device of claim 41, wherein the collection reservoir contains a background ion in a formulation additionally comprising a vehicle suitable for transdermal analyte extraction.

58. The device of claim 41, wherein the first electrode assembly comprises a reservoir electrode adapted to be placed in agent transmitting relation with a body tissue and having a receptacle to collect the target analyte.

59. The device of claim 41, wherein said region of tissue has an area in the range of less than approximately 1 cm² to greater than 100 cm².

60. The device of claim 59, wherein the said region of tissue has an area in the range of 5 cm² to 30 cm².

61. The device of claim 41, wherein the device is suitable for analyte extraction that is carried out for a time period in the range of less than 10 minutes to greater than 72 hours.

62. The device of claim 61, wherein the device is suitable for analyte extraction that is carried out for a time period in the range of about 1 hour to 12 hours.

63. The device of claim 61, wherein the device is suitable for analyte extraction that is carried out for a time period in the range of about 12 hours to 24 hours.

64. In a method for extracting a permeant across body tissue using electrical current, the improvement comprising transporting, at the same time and in a different direction of the analyte, at least one background ion having a hindrances factor that changes at a faster rate than the hindrance factor of the co-ion of the analyte in the body, whereby changes in permeant flux are minimized and intertissue variability is reduced.

65. The method of claim 64, wherein the tissue is skin.

66. The method of claim 64, wherein the tissue is mucosal tissue.

67. A method for extracting an analyte permeant agent across body tissue, comprising:

(a) placing in contact with the body tissue a composition comprising at least one background ion having a hindrance factor that changes at a faster rate than the hindrance factor of the co-ion of the analyte in the body when an electrical current is applied; and

(b) applying an electrical current to the region of tissue, the current of a voltage and duration effective to induce electroporation of the body surface in said tissue.

68. The method of claim 67, wherein the tissue is skin.

69. The method of claim 67, wherein the tissue is mucosal tissue.

70. The device of claim 67, wherein the background ion has an ionic charge that is identical to the ionic charge of the co-ion transported with the permeant.

71. The device of claim 67, wherein the background ion has an ionic charge that exceeds the ionic charge of the co-ion transported with the permeant.

72. The device of claim 67, wherein the background ion has an ionic charge of opposite polarity of the co-ion transported with the permeant.

73. The method of claim 67, wherein the electrical current is applied as a direct. current.

74. The method of claim 67, wherein the electrical current is applied as an alternating current.

75. The method of claim 67, wherein the electrical current is applied as both alternating and direct current superimposed over one another.

76. The method of claim 67, wherein the excipient background ion has an ionic size effective to minimize changes in permeant extraction flux.

77. The method of claim 67, wherein the extracted substance is glucose.

78. The device of claim 67, wherein the extracted substance is phenylalanine.

79. The device of claim 67, wherein the extracted molecules are markers of disease states, pharmaceutical agents administered to the subject, substances of abuse, ethanol, electrolytes, minerals, hormones, peptides, metal ions, nucleic acids, genes, enzymes or any metabolites, conjugates, or other derivations of the aforementioned products.

80. The device of claim 67, wherein the extracted permeant is an oligosaccharide, monosaccharide, organic acid, alcohol, fatty acid, cholesterol and cholesterol-based compound, amino acid, zinc, iron, copper, magnesium and potassium.

81. The device of claim 67, wherein the extracted permeant is a pharmacologically active agents that have been administered for either therapeutic or prophylactic treatment, including analeptic agents;

analgesic agents;

anesthetic agents;

antiasthmatic agents;

antiarthritic agents;

anticancer agents;

anticholinergic agents;

anticonvulsant agents;

antidepressant agents;

antidiabetic agents;

antidiarrheal agents;

antiemetic agents;

antihelminthic agents;

antihistamines;

antihyperlipidemic agents;

antihypertensive agents;

anti-infective agents;

antiinflammatory agents;

antimigraine agents;

antineoplastic agents;

antiparkinsonism drugs;

antipruritic agents;

antipsychotic agents;

antipyretic agents;

antispasmodic agents;

antitubercular agents;

antiulcer agents;

antiviral agents;

anxiolytic agents;

appetite suppressants;

attention deficit disorder and attention deficit hyperactivity disorder drugs;

cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“

CNS”

) agents, beta-blockers and antiarrhythmic agents;

central nervous system stimulants;

diuretics;

genetic materials;

hormonolytics;

hypnotics;

hypoglycemic agents;

immunosuppressive agents;

muscle relaxants;

narcotic antagonists;

nicotine;

nutritional agents;

parasympatholytics;

peptide drugs;

psychostimulants;

sedatives;

steroids;

smoking cessation agents;

sympathomimetics;

tranquilizers;

vasodilators;

β

-agonist; and

tocolytic agents or metabolites thereof.

82. The device of claim 67, wherein the one or more substance is extracted concomitantly.

83. The device of claim 67, wherein the collection reservoir contains a background ion in a formulation additionally comprising a vehicle suitable for transdermal analyte extraction.

84. The device of claim 67, wherein the first electrode assembly comprises a reservoir electrode adapted to be placed in agent transmitting relation with a body tissue and having a receptacle to collect the target analyte and containing the background ion.

85. The device of claim 67, wherein said region of tissue has an area in the range of less than approximately 1 cm² to greater than 100 cm².

86. The device of claim 85, wherein the said region of tissue has an area in the range of 5 cm² to 30 cm².

87. The device of claim 67, wherein the device is suitable for analyte extraction that is carried out for a time period in the range of less than 10 minutes to greater than 72 hours.

88. The device of claim 87, wherein the device is suitable for analyte extraction that is carried out for a time period in the range of about 1 hour to 12 hours.

89. The device of claim 87, wherein the device is suitable for analyte extraction that is carried out for a time period in the range of about 12 hours to 24 hours.